These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 35780952

  • 1. Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy.
    Quick J, Santos ND, Cheng MHY, Chander N, Brimacombe CA, Kulkarni J, van der Meel R, Tam YYC, Witzigmann D, Cullis PR.
    J Control Release; 2022 Sep; 349():174-183. PubMed ID: 35780952
    [Abstract] [Full Text] [Related]

  • 2. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.
    Lee JB, Zhang K, Tam YY, Tam YK, Belliveau NM, Sung VY, Lin PJ, LeBlanc E, Ciufolini MA, Rennie PS, Cullis PR.
    Int J Cancer; 2012 Sep 01; 131(5):E781-90. PubMed ID: 22095615
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation.
    Nakata D, Nakao S, Nakayama K, Araki S, Nakayama Y, Aparicio S, Hara T, Nakanishi A.
    Biochem Biophys Res Commun; 2017 Jan 29; 483(1):271-276. PubMed ID: 28025139
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
    Singh KB, Ji X, Singh SV.
    Mol Cancer Ther; 2018 Oct 29; 17(10):2079-2090. PubMed ID: 30030299
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer.
    Andolfi C, Bartolini C, Morales E, Gündoğdu B, Puhr M, Guzman J, Wach S, Taubert H, Aigner A, Eder IE, Handle F, Culig Z.
    Endocrinology; 2024 Aug 27; 165(10):. PubMed ID: 39253786
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.
    Szafran AT, Stephan C, Bolt M, Mancini MG, Marcelli M, Mancini MA.
    Prostate; 2017 Jan 27; 77(1):82-93. PubMed ID: 27699828
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
    Ben Jemaa A, Sallami S, Céraline J, Oueslati R.
    Cell Biol Int; 2013 May 27; 37(5):464-70. PubMed ID: 23418075
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
    Krause WC, Shafi AA, Nakka M, Weigel NL.
    Int J Biochem Cell Biol; 2014 Sep 27; 54():49-59. PubMed ID: 25008967
    [Abstract] [Full Text] [Related]

  • 20. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Khurana N, Kim H, Chandra PK, Talwar S, Sharma P, Abdel-Mageed AB, Sikka SC, Mondal D.
    Oncol Rep; 2017 Nov 27; 38(5):2774-2786. PubMed ID: 28901514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.